96 episodes

Molecule to Market takes you inside the contract outsourcing space with industry insights and thoughts direct from the brains of the people that make the headlines (just think of your favourite podcast and that’s what we’re doing, but with drug supply chain shortages instead of unsolved crimes and life science leaders instead of sports stars). Talking everything from pharmaceutical contract research, development and manufacturing to clinical trial packaging, logistics and technology – Molecule to Market is a vital shot of infotainment for anyone who wants in on outsourcing.

Molecule to Market: Inside the outsourcing space Raman Sehgal

    • Science
    • 5.0 • 22 Ratings

Molecule to Market takes you inside the contract outsourcing space with industry insights and thoughts direct from the brains of the people that make the headlines (just think of your favourite podcast and that’s what we’re doing, but with drug supply chain shortages instead of unsolved crimes and life science leaders instead of sports stars). Talking everything from pharmaceutical contract research, development and manufacturing to clinical trial packaging, logistics and technology – Molecule to Market is a vital shot of infotainment for anyone who wants in on outsourcing.

    Top 5 episodes of all time

    Top 5 episodes of all time

    As we celebrate the podcast hitting 30,000 downloads and approaching its 100th episode, Raman reflects on the most downloaded episodes with highlights from the top 5.  
    In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector, diving into the top 5 episodes of all time, featuring:
    JoyL Silva, Pfizer CentreOne discussing: her early career journey and advice, industry trends, and personalized medicines
    Tia Lyles-Williams, LucasPye Bio discussing: equality & diversity, Covid-19’s impact, fundraising and providing opportunities to the next generation  
    Gerry Cox, Velesco Pharma Services discussing: client relationships, starting a new business and his advice 
    Cory Lewis, INCOG BioPharma discussing: acquisitions, turning around a business, and lessons from the franchise model 
    Allan Shaw, Industry Consultant discussing: biotech trends, commonalities & challenges, and the supply chain ecosystem
    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 
    Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

    • 34 min
    CPHI 2022 - Trends, challenges & opportunities

    CPHI 2022 - Trends, challenges & opportunities

    In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who discusses emerging trends and challenges for the life sciences sector live from CPHI Frankfurt 2022, with:
    Grainne Hughes, Vice President of Business Support Operations at Almac 
    Christine Fürst, Senior Director Key Account Manager Europe at Vetter Pharma 
    Guido Wallraff, Corporate Business Development Director at Ardena
    Jenny Gattari, CDMO Business Development Lead (North America) at Pfizer CentreOne 
    Brittany Hayes, Director of Global Highly Potent & Oncology Platform at CordenPharma
    Listen to this episode to find out more about these companies and gain an insight into the changes and demands they see coming in 2023. They also discuss their experience of CPHI this year, how it compares to last year’s event and what trends they have noticed across their exploration of the Messe. 
    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 
    Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

    • 23 min
    Views from AAPS 2022

    Views from AAPS 2022

    In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who discusses future industry trends live from AAPS Boston 2022, with:

    Casey Franklin, VP of Business Development at Alcami

    Umberto Romeo, R&D Manager at Corden Pharma

    Steven Dodd, Executive Director for sales strategy at Icon CRO

    Paul Dickinson, Founder & CSO at Seda Pharmaceutical Development Services

    Raman finds out more about the exciting opportunities coming up for these companies in 2023 and beyond, as well as scoring the inside scoop on trends our guests foresee both within their business and the wider industry. 

    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

    Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

    • 15 min
    The Personalized Medicine Pioneer

    The Personalized Medicine Pioneer

    In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with David Katz, Founder & CSO at Sparrow Pharmaceuticals, Inc.Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:
    The contrast of developing new drugs and running clinical trials in a big pharma versus his journey as the founder of a virtual biopharma company.
    What life really looks like and skills you have to develop in a firm developing novel, targeted therapies to address unmet patient needs.
    Some of the options, decisions and pathways to commercialization that a Phase 2 biopharma business has to consider.
    The inspiration, leadership learnings and brand influence of a famous Hollywood character.
    Prior to founding Sparrow, David was a pharmaceutical R&D leader at Abbott and AbbVie, where he led clinical development and drug discovery teams, and was a personalized medicine pioneer. David is dedicated to the mentorship of the next generation of life sciences entrepreneurs, currently as an entrepreneur-in-residence at Oregon Health & Science University. He held post-doctoral fellowships in immunology at the Universities of Chicago and Michigan, earned MPhil and PhD degrees in Molecular Biophysics and Biochemistry from Yale University, and is an alumnus of Pomona College (BA, Chemistry). David has published over 50 peer-reviewed scientific papers and in his copious spare time, he is actively involved in new play development and is a glass artist.
    Don't forget to subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
    Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.
     

    • 50 min
    Inizio’s biotech bromance

    Inizio’s biotech bromance

    In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jason McKenna, Global President, and Dean McAlister, Executive Vice President both from Inizio Biotech.Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with the dynamic duo, covering:
    A wealth of big pharma learnings for today’s emerging biotechs.
    The (good and bad) impact of the current biotech capital market slowdown on decision-making for outsourced service providers.
    What the future may look like in our space in terms of financing and therapeutic impact.
    Learnings from how to make a business relationship successes from complementary colleagues.
    Jason spent the initial part of his career in big pharma, working for AstraZeneca in the US and UK across a variety of marketing, sales and finance roles. He is now the Global President of Inizio’s first enterprise business unit, Inizio Biotech. Jason and his team enable biotech partners to maximize the value of their assets by providing scalable support, through the seamless experience of a single point of coordination. Previously CEO at STEM, an Inizio Advisory company, Jason led the organization through significant scaling and transformation throughout the COVID pandemic.
    Dean has over 35 years of biopharma experience across established and startup organizations – including 28 years with AstraZeneca in 16 roles of increasing commercial responsibility, where he led global and regional sales and strategic business development. Dean has built cross-functional teams spanning all therapeutic areas. Following AZ, he grew STEM Healthcare North America from 10 clients to 38 over a five-year period before a sale to UDG. He is also a podcaster, speaker, and published author.
    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
    Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

    • 45 min
    The Magic of Drug Development

    The Magic of Drug Development

    In this special episode of Molecule to Market, we go back inside the global drug development space with Marcelo Bigal, President and CEO, of Ventus Therapeutics, and Versant Venture Partner, who shares his journey from being a neurologist to taking a drug to market when he became part of Teva Pharmaceuticals and now is a CEO.
    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Marcelo, covering: 
    What it feels like to take a drug from the laboratory to market and what really goes into that process.
    The company’s phenomenal attitude toward patients and how this is exemplified in its drug development. 
    The incredible story of the company he joined and how 14 months after a fundraiser it was acquired by Teva Pharmaceuticals for $825M.
    The current state of the capital market and where future opportunities may lie for the business. 
    The challenging area of drug development in biotechnology over the last three years. 
    Marcelo brings more than 13 years of pharma experience with a focus on urology spanning r&d, medical and scientific affairs. He has extensive experience in leading large and small scientific groups, including multiple leadership roles in industry, including the Chief Scientific Officer at Teva as well as Chief Medical Officer at Teva and Purdue. Prior to his work in the pharma sector, Marcelo was a faculty member of the Albert Einstein College of Medicine, Department of Neurology, as well as the director of research at the New England Centre for headache. 
    He has authored no fewer than 330 papers in peer-reviewed journals, edited six books in urology and is the recipient of multiple awards and recognitions in the field. Marcelo holds a medical doctorate degree from the College of Medicine at the University of Sao Paulo, Brazil, where he obtained a master’s in science and a PhD in neurosciences. He completed his postdoctoral research at the New England Centre for headache.

    • 53 min

Customer Reviews

5.0 out of 5
22 Ratings

22 Ratings

Maryhuston ,

Awesome!

Truly awesome to listen Raman’s shows. He brings out the best of the bests. Thoroughly enjoy his show! Good luck Raman!

C-Lo-77 ,

Great insights!

Raman does a wonderful job with capturing insights across the industry and with experts.

Adam g 1991 ,

Great outsourcing market info

Very very smart mann

Top Podcasts In Science

Hidden Brain
Alie Ward
Freakonomics Radio + Stitcher
Neil deGrasse Tyson
Vox
Sam Harris

You Might Also Like

Bloomberg
Goldman Sachs
Colossus | Investing & Business Podcasts
Hugh MacArthur, Bain & Company
STAT
Financial Times